Search CommunityWalk:


Functional Genetics Inc. (FGI)

708 Quince Orchard Road
Gaithersburg, MD, USA

Category: Biotechnology/Biopharmaceutical

Used in the following map:

Maryland Biotech Industry Map

Functional Genetics Inc. (FGI) is a biotechnology company focused on the development of antiviral drugs that can prevent or treat a broad spectrum of different viral diseases. The company has started its operations from 2001 to capitalize on a new technology for target discovery, Random Homozygous Gene Perturbation (RHGP). It was co-founded by Stanley N. Cohen.

FGI's core discovery technology, Random Homozygous Gene Perturbation (RHGP), combines molecular biology and functional understanding of cell behaviour to find elegant solutions to complex biological problems. RHGP can efficiently interrogate every gene in a cell, both for gain or loss of target function, and efficiently focus upon those targets that directly cause the desired experimental outcome. RHGP centers upon the use of a novel genetic element, known as a Gene Search Vector (GSV), which can probe the entire genome to up- or down-regulate each target in a cell. The company utilizes RHGP to identify novel targets with applications to cancer (targets that cause chemotherapy resistance or metastasis), infectious disease (targets for broad-spectrum antivirals and antibiotics), Alzheimer's disease (targets that cause amyloid plaques), manufacturing of biologics (pathways that increase the efficiency of monoclonal antibody production), and other indications.

FGI has developed a portfolio of broad-spectrum antiviral products and discovery technologies. Its product pipeline includes small molecule therapeutics and monoclonal antibodies. Its commercial product focus has targeted three broad areas: Respiratory viruses (Respiratory Syncytial Virus (RSV), Influenza), Hepatitis viruses (HBV, HCV) and Sexually-transmitted viruses (HIV, Herpes). The company's government product focus is on the hemorrhagic fever viruses (Ebola, Marburg, Lassa).

FGI's products include: FGI-101-1A6, a fully human monoclonal antibody that targets a host protein, TSG101, which is uniquely exposed on the surface of virus-infected cells; FGI-102-100, a small molecule therapeutic that selectively binds TSG101, a host protein that is 'hijacked' to support the dissemination of enveloped viruses from infected cells; FGI-103-723, a small molecule therapeutic that has demonstrated impressive abilities to prevent or treat infections caused by a broad spectrum of different viral pathogens, including respiratory syncytial virus (RSV) and other paramyxoviruses; FGI-110 program, which is developing fully human antibodies for the treatment or prevention of respiratory infections; and FGI-111 program, which is developing fully human antibodies for the treatment or prevention of sexually transmitted diseases. Its core discovery engine, RHGP, identified Robo1 as a target for a broad spectrum medicine to treat or prevent infection by sexually-transmitted viruses.

FGI has collaborations with Elanco Animal Health, ProBioGen AG, U.S. Department of Defense, etc.